Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving Average – Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT)’s stock price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.55 and traded as low as $0.49. Vaxart shares last traded at $0.70, with a volume of 28,790,756 shares changing hands.

Analyst Ratings Changes

VXRT has been the topic of a number of recent analyst reports. B. Riley dropped their target price on shares of Vaxart from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Thursday, March 27th. Wall Street Zen raised shares of Vaxart to a “hold” rating in a research report on Thursday, May 22nd.

Vaxart Stock Performance

The stock’s 50-day moving average is $0.42 and its 200 day moving average is $0.55. The stock has a market capitalization of $160.27 million, a PE ratio of -1.71 and a beta of 1.25.

Vaxart (NASDAQ:VXRT) last posted its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.07) EPS for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $20.88 million for the quarter, compared to the consensus estimate of $2.85 million. Vaxart had a negative net margin of 431.61% and a negative return on equity of 110.46%. Analysts expect that Vaxart, Inc. will post -0.39 earnings per share for the current year.

Insider Activity at Vaxart

In other Vaxart news, insider Steven Lo purchased 100,000 shares of the firm’s stock in a transaction that occurred on Monday, May 19th. The stock was purchased at an average price of $0.49 per share, for a total transaction of $49,000.00. Following the purchase, the insider now directly owns 100,000 shares in the company, valued at approximately $49,000. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 2.90% of the company’s stock.

Institutional Trading of Vaxart

A number of large investors have recently bought and sold shares of VXRT. Jones Financial Companies Lllp boosted its stake in Vaxart by 276,364.7% during the 1st quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares during the period. Squarepoint Ops LLC boosted its stake in Vaxart by 95.0% during the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock worth $342,000 after purchasing an additional 251,789 shares during the period. Raymond James Financial Inc. acquired a new stake in Vaxart during the 4th quarter worth $129,000. Virtu Financial LLC acquired a new stake in Vaxart during the 1st quarter worth $56,000. Finally, Silverarc Capital Management LLC boosted its stake in Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock worth $714,000 after purchasing an additional 77,782 shares during the period. Institutional investors and hedge funds own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.